Fort Worth-based NanOlogy, a clinical-stage oncology company, on Tuesday announced the appointment of John M. Goldberg as fractional chief medical officer to advance development of its Large Surface Area Microparticle (LSAM) drug portfolio, including its development program targeting Diffuse Intrinsic Pontine Glioma (DIPG), a devastating pediatric brain cancer with limited treatment options.
Goldberg is a graduate of the University of Massachusetts Chan Medical School and is board-certified in pediatric hematology/oncology, with more than 20 years of experience across all phases of drug development, from early research through late-phase clinical trials.
His most recent roles as chief medical officer included positions at Rafael Holding Inc., a healthcare investment, family office, and biotechnology company, and at Oncorus Inc., a biopharmaceutical company developing an intratumorally delivered viral immunotherapy for cancer.
Earlier in his career, Goldberg served as senior medical director at H3 Biomedicine Inc., a research subsidiary of Eisai, and as medical director at Agenus, Inc. He also held academic appointments as a part-time lecturer at Harvard Medical School and associate professor at the University of Miami Miller School of Medicine.
“As we progress our DIPG program toward initiating a clinical trial in late 2026 and advance our clinical-stage investigational drugs into late-phase clinical trials, John will play a critical role in our development strategy and execution,” said David Arthur, CEO of NanOlogy, in a statement. “John’s broad expertise across both drug development and business strategy will strengthen our ability to rapidly advance these programs.”
Said Goldberg: “My initial priorities are to advance the DIPG program and select the best clinical pathway for our adult solid tumor investigational drugs. I am looking forward to our progress and the benefit it may hold for cancer patients.”
NanOlogy is a private clinical-stage oncology company developing treatments for solid tumors using drugs optimized for intratumoral delivery designed to improve response with minimal to no systemic toxicity. Enabled by the CritiTech Particle Engineering Solutions’ Purcision™ technology platform, the company produces LSAMs of pure drug for direct local delivery. NanOlogy clinical programs have advanced LSAM investigational drugs in multiple solid tumors and are supported by an extensive intellectual property portfolio of more than 100 issued patents worldwide.